Industry Focus

Motley Fool's Michael Douglass and Todd Campbell shed light on how Celgene's deal-making frenzy positions it as a potential MS leader and offer up insight into how to value immuno-oncology stocks.

Direct download: 150715_IF_Healthcare.mp3
Category:Podcast -- posted at: 5:47pm EST